PROM1 and familial pancreatic carcinoma: However, the possible clinical significance of CD133 expression in pancreatic cancer has not been investigated using immunohistochemistry, which is considered a difficult technique because of the inability to detect small numbers of putative stem cells (Miki et al, 2007).